⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28418210 | 0.62 | — | — | |
| SCHEMBL16179060 | 0.61 | — | — | |
| SCHEMBL4078808 | 0.56 | — | — | |
| SCHEMBL1720840 | 0.56 | — | — | |
| SCHEMBL11266465 | 0.56 | — | — | |
| SCHEMBL13210386 | 0.54 | — | — | |
| SCHEMBL10917711 | 0.50 | — | — | |
| Ammonia Solution, Strong SCHEMBL8471093 | 0.46 | CRBN (0.44) | — | |
| Hydrochloric Acid SCHEMBL7938304 | 0.46 | — | — | |
| Hydrochloric Acid SCHEMBL7938305 | 0.44 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0961775-B1 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6479463-B1 | USED TO TREAT AN INFECTION, AN INFESTATION, A NEOPLASM, OR AN AUTOIMMUNE DISEASE OR TO MODULATE ASPECTS OF THE IMMUNE SYSTEM, INCLUDING MODULATION OF TH1 AND TH2 | ICN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | AVERETT DEVRON R (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0961775-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998016184-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |